Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference
HOUSTON, Dec. 3, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present animal...
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
Priority Review Vouchers subject to approved NDAHOUSTON, Dec. 1, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and...
Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML
Experimental data to be presented at American Society for Hematology Annual ConferenceHOUSTON, Nov. 19, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020
HOUSTON, Nov. 13, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the...
Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19
Initial information sharing agreement signed to further research into the anti-viral potential of WP1122HOUSTON, Oct. 29, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of...
Moleculin to Participate in Panel at ROTH Capital’s “COVID-19 Therapeutics in Development” Healthcare Event
HOUSTON, Oct. 27, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that...
Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors
Annamycin demonstrated up to 30-fold greater concentration in lungs of Annamycin than the current standard of care drug; enables targeting cancer in its sanctuary siteHOUSTON, Oct. 21, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a...
Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial
Adult brain tumor trial advances to final dose escalation cohort of WP1066 HOUSTON, Oct. 13, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV
Also shows activity in Zika and Dengue FeverHOUSTON, Oct. 6, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the...
Moleculin Appoints Elizabeth Cermak to Board of Directors
HOUSTON, Oct. 5. 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, today announced the...